Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e
Regulators in the US and EU have started a review of Pfizer's S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions e
The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC).
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD).
It's only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping for with etrasimod, the main asset in the
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio